Table 5.

The association of gender with PsA life impact and disease activity over time among 458 psoriatic arthritis patients.

Model covariates	Logistic regression Outcome PsAID≥4, OR (95% CI), p-value		Linear regression Outcome PsAID Beta coefficient (95% CI), p-value
Simple models adjusted for age and PsA duration
Gender	2.71 (1.85, 3.97)	<0.001	1.37 (0.94, 1.79)	<0.001
Follow-up time (months)	0.96 (0.88, 1.04)	0.306	−0.01 (−0.09, 0.07)	0.769
Follow-up time × Gender*	0.91 (0.81, 1.02)	0.095	−0.18 (−0.29, −0.06)	0.003
Multivariable models adjusted for age and PsA duration
Gender*	2.3 (1.49, 3.55)	<0.001	0.99 (0.60, 1.38)	<0.001
Follow-up time (months)	0.93 (0.85, 1.03)	0.170	−0.02 (−0.10, 0.05)	0.598
Follow-up time × Gender	0.94 (0.82, 1.07)	0.335	−0.12 (−0.23, −0.02)	0.023
Comorbidity	1.22 (1.07, 1.39)	0.002	0.18 (0.08, 0.28)	0.001
TJC68	1.10 (1.06, 1.14)	< 0.001	0.08 (0.06, 0.10)	< 0.001
SJC66	1.02 (0.98, 1.07)	0.399	0.02 (−0.01, 0.06)	0.125
LEI	1.34 (1.14, 1.57)	< 0.001	0.37 (0.24, 0.50)	< 0.001
Psoriasis BSA >5%	0.99 (0.96, 1.02)	0.567	0.00 (−0.03, 0.03)	0.949
CRP (mg/dL)	1.04 (0.26, 1.75)	0.891	0.45 (−0.01, 0.91)	0.054
Current bDMARD	1.23 (0.87, 1.75)	0.244	−0.06 (−0.36, 0.25)	0.722

Notations:

^*interaction term between follow-up time in weeks and gender. Bold font designates significant p-values. Abbreviations: TJC68 tender joint count range 0–68, SJC66 swollen joint count range 0–66, LEI Leeds enthesitis index range 0–6, VAS visual analog scale range 0–10, HAQ-DI Health Assessment Questionnaire Disability index range 0–3, BSA body surface area range 0–100%, bDMARD biologic Disease Modifying Rheumatic Drug.

Missing values for (women, men): TJC68 (0,2), SJC66 (0,2), Pain VAS (1,1), Patient global VAS (1,2)